Amarin Co. plc (NASDAQ:AMRN – Get Rating) Director Olsen Per Wold acquired 55,000 shares of the business’s stock in a transaction dated Monday, June 13th. The shares were acquired at an average cost of $1.69 per share, with a total value of $92,950.00. Following the acquisition, the director now directly owns 149,000 shares of the company’s stock, valued at approximately $251,810. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
AMRN stock opened at $1.81 on Thursday. The firm’s 50-day moving average price is $2.11 and its two-hundred day moving average price is $2.92. Amarin Co. plc has a 12-month low of $1.11 and a 12-month high of $5.97. The stock has a market capitalization of $718.58 million, a price-to-earnings ratio of -36.19 and a beta of 2.12.
Amarin (NASDAQ:AMRN – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.06). Amarin had a negative net margin of 4.15% and a negative return on equity of 1.31%. The firm had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $128.21 million. During the same quarter in the previous year, the firm posted $0.03 EPS. Amarin’s revenue was down 33.5% compared to the same quarter last year. On average, research analysts expect that Amarin Co. plc will post -0.18 EPS for the current fiscal year.
AMRN has been the subject of several recent analyst reports. SVB Leerink lowered Amarin from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $10.00 to $3.00 in a report on Thursday, May 5th. StockNews.com raised Amarin from a “sell” rating to a “hold” rating in a research note on Saturday, June 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Amarin in a research note on Wednesday, March 2nd. Northland Securities lowered Amarin from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 4th. Finally, JPMorgan Chase & Co. lowered Amarin from a “neutral” rating to an “underweight” rating in a research note on Friday, May 6th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.50.
Several hedge funds and other institutional investors have recently made changes to their positions in AMRN. Invesco Ltd. purchased a new position in shares of Amarin during the second quarter valued at about $87,000. BlackRock Inc. lifted its stake in shares of Amarin by 18.7% in the third quarter. BlackRock Inc. now owns 197,767 shares of the biopharmaceutical company’s stock worth $1,008,000 after buying an additional 31,112 shares in the last quarter. Morgan Stanley lifted its stake in shares of Amarin by 0.7% in the third quarter. Morgan Stanley now owns 6,336,406 shares of the biopharmaceutical company’s stock worth $32,315,000 after buying an additional 41,332 shares in the last quarter. Jacobi Capital Management LLC lifted its stake in shares of Amarin by 977.8% in the third quarter. Jacobi Capital Management LLC now owns 4,850 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,400 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Amarin by 138.6% in the third quarter. Royal Bank of Canada now owns 71,602 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 41,587 shares in the last quarter. Institutional investors own 35.42% of the company’s stock.
About Amarin (Get Rating)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Read More
Receive News & Ratings for Amarin Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amarin and related companies with MarketBeat.com’s FREE daily email newsletter.
George is Digismak’s reported cum editor with 13 years of experience in Journalism